Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Consensus PT from Analysts

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $10.80.

RGLS has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a report on Monday, November 11th. StockNews.com raised Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th.

Regulus Therapeutics Price Performance

Shares of NASDAQ:RGLS opened at $1.23 on Friday. The business’s 50 day moving average price is $1.53 and its 200-day moving average price is $1.59. Regulus Therapeutics has a 1 year low of $1.08 and a 1 year high of $3.79. The firm has a market capitalization of $80.24 million, a price-to-earnings ratio of -1.14 and a beta of 1.60.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, sell-side analysts expect that Regulus Therapeutics will post -0.88 earnings per share for the current year.

Institutional Trading of Regulus Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Creative Planning acquired a new position in shares of Regulus Therapeutics during the 3rd quarter valued at about $26,000. SG Americas Securities LLC purchased a new position in Regulus Therapeutics during the third quarter worth about $33,000. Jane Street Group LLC acquired a new position in Regulus Therapeutics in the 3rd quarter valued at about $46,000. JPMorgan Chase & Co. grew its stake in shares of Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 52,059 shares during the period. Finally, Barclays PLC increased its holdings in shares of Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 62,549 shares during the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.